Table 1. Baseline clinical and echocardiographic characteristics of the study population.
| Characteristics | n (%) or mean (SD) | |
|---|---|---|
| Age; years | 63.51 (10.6) | |
| Sex (male) | 777 (69.3) | |
| Height; cm | 168.02 (9.19) | |
| Weight; Kg | 82.5 (14.25) | |
| Body surface; m2 | 1.92 (0.19) | |
| Body mass index; Kg/m2 | 29.22 (4.58) | |
| Normal weight (18.5–24.9 Kg/m2) | 187 (16.7) | |
| Overweight (25–29.9 Kg/m2) | 508 (45.3) | |
| Obesity (≥ 30 Kg/m2) | 426 (38) | |
| Hypertension | 610 (54.4) | |
| Diabetes mellitus | 180 (16.1) | |
| COPD | 84 (7.5) | |
| Previous embolism | 64 (5.7) | |
| Previous ECV | 198 (17.7) | |
| AF duration > 1 year | 168 (15,0) | |
| NYHA functional class | I | 772 (68.8) |
| ≥ II | 349 (31.2) | |
| LA AP diameter (mm) | 43,37 (5.5) | |
| LA AP diameter ≥ 50 mm | 138 (12.3) | |
| LVEF (%) | 61.55 (8.15) | |
| Antiarrhythmic drugs post-ECV | 900 (80.3) | |
| Amiodarone | 616 (55) | |
| Ic class antiarrythmic drugs | 278 (24.8) | |
| Other antiarrythmic drugs | 6 (0.5) | |
AF = atrial fibrillation; AP = anteroposterior; COPD = chronic obstructive pulmonary disease; ECV = electrical cardioversion; LA = left atrium; LVEF = left ventricle ejection fraction; NYHA = New York Heart Association